WeVote
Log In

Bill

Bill

HB 2083

RELATING TO THE PROMOTION OF CONTROLLED SUBSTANCES.

2026 Regular Session Introduced by Nadine Nakamura

Hawaii HB 2083 regulates controlled substance promotion through House Health and Judiciary committees, but full provisions unavailable for detailed policy assessment.

Reported from HSH (Stand. Com. Rep. No. 375-26) as amended in HD 1, recommending passage on Second Reading and referral to JHA.
#criminaloffenses #drug-freezones #homelessfacilities #homelessness #honoluluprosecutingattorneypackage #housing #promotingcontrolledsubstances #shelter
0
WeVote Research Nonpartisan
Bill Summary · HB 2083

Legislative bill overview

HB 2083 appears to address the promotion or regulation of controlled substances in Hawaii, though the specific provisions are not detailed in the available legislative history. The bill was introduced by Representative Nadine Nakamura and has been referred to the House Health (HSH) and Judiciary and Hawaiian Affairs (JHA) committees, suggesting it involves both public health and legal dimensions.

Why is this important

Legislation affecting controlled substances carries significant implications for public health policy, criminal justice, medical practice, and enforcement priorities in Hawaii. The dual committee referral indicates the bill may involve complex intersections between health regulations and legal frameworks that affect residents and state resources.

Potential points of contention

  • Ambiguous title language: The phrase "promotion of controlled substances" could mean either restricting promotion (advertising/marketing) or facilitating access, creating uncertainty about the bill's actual intent without seeing the full text
  • Committee jurisdiction overlap: Referral to both health and judiciary committees may indicate competing policy priorities or unclear legislative scope that could produce disagreement during deliberation
  • Missing bill details: The summary provided contains no specific provisions, making it impossible to assess whether the bill expands access, restricts marketing, affects medical cannabis, or addresses other substance-related policies

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.